NGL Fine-Chem Limited (NGLFINE.BO)

INR 2040.15

(2.62%)

Market Cap (In INR)

12.6 Billion

Revenue (In INR)

3.38 Billion

Net Income (In INR)

413.16 Million

Avg. Volume

700.00

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1728.6-2822.5
PE
-
EPS
-
Beta Value
1.08
ISIN
INE887E01022
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Rahul Jayant Nachane
Employee Count
-
Website
https://www.nglfinechem.com
Ipo Date
Details
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, xylazine hydrochloride, and marbofloxacin for animal health applications; and nitazoxanide and atovaquone for human health applications. The company provides various intermediate products and specialty chemicals; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.